How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) issued its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). The firm earned $15.68 million during the quarter, compared to analyst estimates of $15.80 million.

What other stocks do shareholders of Forty Seven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE) , Energy Transfer (ET) , TG Therapeutics (TGTX) , Gilead Sciences (gild) , Unisys (UIS) , Inovio Pharmaceuticals (INO) , GlycoMimetics (GLYC) , NVIDIA (NVDA) , ACADIA Pharmaceuticals (ACAD) and Sarepta Therapeutics (SRPT) .

When did Forty Seven IPO?

Forty Seven (FTSV) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

NASDAQ:FTSV

Forty Seven (FTSV) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free FTSV Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $95.51
▼
$95.51
50-Day Range: $95.51
▼
$95.51
52-Week Range: $5.53
▼
$95.51

Volume: N/A
Average Volume: 1.61 million shs
Market Capitalization: $4.60 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Forty Seven alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Forty Seven Stock (NASDAQ:FTSV)

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

FTSV Stock News Headlines

April 9, 2024 | msn.com

49ers sign veteran tight end

March 28, 2024 | msn.com

Parent Of FTX Victim Who Lost $130K Recommends Six-Year Sentence For Sam Bankman-Fried, Countering DOJ's 40-50 Years

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

November 16, 2023 | morningstar.com

Formula Systems (1985) Ltd ADR FORTY

October 27, 2023 | nypost.com

Six young men found dead, one injured in search for seven abducted Mexican teenagers

October 10, 2023 | bizjournals.com

$18M upgrade makes historic downtown Milwaukee high-rise a modern data center

September 11, 2023 | msn.com

Tampa radio station 101.5 has changed from Top 40 to R&B format

August 18, 2023 | msn.com

JRA Chair: Seven businesses coming to Farish Street

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

June 11, 2023 | dailymail.co.uk

Week one: seven-day detox

April 18, 2023 | dailymail.co.uk

I'm a fitness coach. These are the seven exercises that are a complete waste of your time

March 22, 2023 | thetimes.co.uk

Forty racists beat me with sticks in the name of a conspiracy theory

January 2, 2023 | finance.yahoo.com

Forty-Five Percent of Public Schools Operating Without a Full Teaching Staff in October, New NCES Data Show

October 1, 2022 | bizjournals.com

Meet our Forty Under 40 winners

June 18, 2022 | news.yahoo.com

South wins 51st Ken Lantzy Finest 40 All-Star Classic in shootout

May 27, 2022 | investing.com

FTSV_old Historical Data

See More Headlines

Receive FTSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:FTSV
CUSIP: N/A
CIK: N/A
Web: www.fortyseveninc.com
Phone: 650-352-4150
Fax: N/A
Employees: 57
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,620,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -50.38%
Return on Assets: -44.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.81
Quick Ratio: 14.81

Sales & Book Value

Annual Sales: $15.68 million
Price / Sales: 293.33
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.52 per share
Price / Book: 12.70

Miscellaneous

Outstanding Shares: 48,156,000
Free Float: N/A
Market Cap: $4.60 billion
Optionable: Not Optionable
Beta: 0.40

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Mark A. McCamish (Age 66)
Pres, CEO & Director
Dr. Craig S. Gibbs (Age 56)
Chief Bus. Officer
Dr. Chris H. Takimoto M.D. (Age 60)
Ph.D., Chief Medical Officer
Mr. Mark Chao
Founder & VP of Clinical Devel.
Mr. Jens-Peter Volkmer
Founder and VP of Research & Early Devel.

Key Competitors

View All Competitors

FTSV Stock Analysis - Frequently Asked Questions

How were Forty Seven's earnings last quarter?: Forty Seven Inc (NASDAQ:FTSV) issued its earnings results on Tuesday, November, 12th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). The firm earned $15.68 million during the quarter, compared to analyst estimates of $15.80 million.
What other stocks do shareholders of Forty Seven own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer (ET), TG Therapeutics (TGTX), Gilead Sciences (gild), Unisys (UIS), Inovio Pharmaceuticals (INO), GlycoMimetics (GLYC), NVIDIA (NVDA), ACADIA Pharmaceuticals (ACAD) and Sarepta Therapeutics (SRPT).
When did Forty Seven IPO?: Forty Seven (FTSV) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

This page (NASDAQ:FTSV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Forty Seven (FTSV) Stock Price, News & Analysis

About Forty Seven Stock (NASDAQ:FTSV)

FTSV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

FTSV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info